The Versamune® nano-platform is based on synthetic positively-charged lipids. The proprietary technology is protected by several patents.

The technology works when administered together with a disease or cancer-specific antigen to prime and target a T-cell response specifically against cells displaying the particular antigen,  Treatment with the Versamune-based immunotherapies result in a stimulation of both the innate and adaptive arms of the immune system. Preclinical studies also suggest significant reduction in the tumors defense mechanisms leading to powerful anti-tumor efficacy.

The versamune platform is built on critical components of cancer immunotherapy that have been demonstrated in the field of tumor immunology and various clinical studies to be clinically important.

PDS Biotechnology illustration
  • About Us

    PDS Biotechnology Corporation logo image

    PDS Biotechnology is a clinical stage biopharmaceutical company developing novel cancer immunotherapies and vaccines for infectious diseases.

  • Contact Us

    PDS Biotechnology Corporation
    Commercialization Center for Innovative Technologies (CCIT)

    675 US Highway one
    North Brunswick, NJ 08902

    Tel: 732-640-0145
    Fax: 732-640-0144